Catalog No.
PAB90001
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Eculizumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Soliris.
Specificity
The product is specific for Eculizumab. This antibody serves as an excellent positive control for Eculizumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 219685-50-4
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica., PMID:40506785
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618
Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how., PMID:40505554
[A case of paroxysmal nocturnal hemoglobinuria treated with eculizumab in unintended pregnancy]., PMID:40484825
[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823
Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis., PMID:40453104
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242
Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature., PMID:40414204
Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis., PMID:40392453
PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database., PMID:40375186
Advancements in Complement Inhibition for PNH and Primary Complement Mediated Thrombotic Microangiopathy., PMID:40354320
Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials., PMID:40346603
Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis., PMID:40341411
Interferon Causes Endothelial Injury in Humans., PMID:40326264
Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120
Complement dysregulation at lymphatics., PMID:40300720
Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report., PMID:40297820
Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics., PMID:40292035
Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice., PMID:40283639
Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report., PMID:40264782
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment., PMID:40257298
Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis., PMID:40244439
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension., PMID:40241307
[Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria]., PMID:40237732
Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients: A case report., PMID:40228287
Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation., PMID:40225375
Macrophage activation syndrome successfully treated with eculizumab and emapalumab: a case report., PMID:40196116
The Crosstalk Between NETs and the Complement Cascade: An Overview in Nephrological Autoimmune Disease., PMID:40141431
Atypical presentation of H1N1-induced thrombotic microangiopathy with CD46 gene mutation
., PMID:40115863
Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis., PMID:40111671
The Critical Importance of Diagnosing Atypical Hemolytic Uremic Syndrome in Postpartum Renal Dysfunction in a Patient With Systemic Lupus Erythematosus: A Case Report and Comprehensive Review., PMID:40092016
Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study., PMID:40068231
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea., PMID:40065454
Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome - a case-series report., PMID:40065282
Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria., PMID:40047384
Ulcerative Colitis Gone Rogue: A Case of Complement-Mediated Thrombotic Microangiopathy in Inflammatory Bowel Disease., PMID:40046371
Eculizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Case Report., PMID:40024618
Prophylactic use of eculizumab for ABO-blood type incompatible kidney transplantation with extremely high ABO-blood type antibody titer: A two case report., PMID:40024311
Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy., PMID:40023814
A hyper-acute immune hemolytic anemia induced by contrast medium was successfully treated with eculizumab: a case report., PMID:40007538
Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review., PMID:39997466
Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study., PMID:39991399
Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study., PMID:39985320
Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders., PMID:39983521
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome., PMID:39982653
High-Throughput Immunoassays for Cavin-4 IgG: A Diagnostic Tool for Immune-Mediated Rippling Muscle Disease., PMID:39957412
Development and application of UHPLC-MS/MS method to quantify eculizumab in PNH patients., PMID:39938137
Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies., PMID:39936529
For research use only. Not for human or drug use.
